

# Events


Speaking Engagement

## ACI 22nd Annual Paragraph IV Conference


When: April 21, 2026 - April 22, 2026  
Location: New York  
People: Aziz Burgy, Ricardo Camposanto

### Related People

---



Aziz Burgy



Ricardo Camposanto

# Related Services

---

## Intellectual Property

---

Axinn partner [Aziz Burgy](#) and counsel [Ricardo Camposanto](#) will speak at American Conference Institute's *Paragraph IV Disputes Conference*, being held April 21-22 in New York.

On April 22, Aziz will speak on the "Ethical Rules and Obligations for the Paragraph IV Practitioner: A Scenario Based Discussion on Professional Responsibility and the Dilemmas that Can Arise" panel. Panelists will discuss:

- Flagging examples of inequitable conduct
- Navigating client communication
- Finding a balance between client interests and expectation and ethical obligations
- Reviewing what constitutes a Rule 11 violation

On April 22, Ricardo will speak on the "Promise and Peril for Patents: Navigating Mandated Disclosures and Clinical Trials as Prior Art" panel. Panelists will discuss:

- Clarifying whether the clinical trial itself is public-use-prior-art
- Determining whether patient confidentiality and other confidentiality agreements amongst clinical investigators eliminate the public use prong of prior art
- Examining how generics are using clinical trial summaries as evidence of obviousness to challenge patents through IPR and the district courts
- Navigating the tension between FDA disclosure rules for clinical trials and IP protection
- Understanding how patent examiners view clinical trials published on [ClinicalTrials.gov](#)
- Analyzing the Federal circuit's assessment of the phrase "clinically proven effective" as support for patent claims in *Bayer v. Mylan*
- Devising filing strategies to maximize patent term while managing risk of invalidation
- Strategizing around dosing regimens that are disclosed prior to efficacy data
- Assessing how the district courts and CAFC have dealt with ongoing clinical trials and whether there is a reasonable expectation of success in the unpredictable arts

To subscribe to our publications, [click here](#).

© 2026 Axinn, Veltrop & Harkrider LLP. All Rights Reserved